Subject Index to Volume 5

INDEX Reviews in Urology Subject Index to Volume 5 5--Reductase inhibitors Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1): S29-S33. Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. 5(suppl 5):S42-S48. Slawin KM. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4):S42-S47; 5(suppl 5):S36-S41. Acquired solitary kidney Shapiro E, Goldfarb DA, Ritchey ML. The congenital and acquired solitary kidney. 5(1):2-8. Acute urinary retention Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5):S28-S35. Nickel JC. Benign prostatic hyperplasia: does prostate size matter? 5(suppl 4):S12-S17. Roehrborn CG. 5--Reductase inhibitors prevent the progression of benign prostatic hyperplasia. 5(suppl 4):S18-S27; 5(suppl 5): S12-S21. Vaughan ED. Long-term experience with 5-reductase inhibitors. 5(suppl 4):S28-S33; 5(suppl 5):S22-S27. Adjuvant chemohormonal therapy Taplin M-E. Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Adjuvant chemotherapy Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42S47; 5(suppl 3):S59-S64. Adverse effects Tenover JL. The androgen-deficient aging male: current treatment options. 5(suppl 1): S22-S28. Aging Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1):S3-S10. Alfuzosin Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. -Adrenergic receptors Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. 5(suppl 5):S42-S48. -Blockers Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. 5(suppl 5):S42-S48. Slawin KM. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4):S42-S47; 5(suppl 5):S36-S41. Androgen Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Androgen ablation Sandler HM, Pienta KJ. Rationale for the radiation therapy oncology group study RTOG P-0014. 5(suppl 2):S28-S34; 5(suppl 3):S45-S51. Androgen blockade Gretzer MB, Partin AW. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. Androgen deficiency Meacham RB. Androgen replacement therapy: treatment advances and clinical implications [Literature Review]. 5(4):245-246. O’Leary MP. Development of an index to evaluate symptoms in men with androgen deficiency. 5(suppl 1):S11-S15. Androgen deprivation Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Androgen-independent prostate cancer Henner WD, Beer TM. A new formulation of calcitriol (DN-101) for high-dose pulse administration in prostate cancer therapy. 5(suppl 3):S38-S44. Leonard GD, Dahut WL, Gulley JL, et al. Docetaxel and thalidomide as a treatment option for androgen-independent, nonmetastatic prostate cancer. 5(suppl 3):S65-S70. Syed S, Tolcher A. Innovative therapies for prostate cancer treatment. 5(suppl 3):S78S84. Androgen-insensitive Taneja SS. A multidisciplinary approach to the management of hormone-refractory prostate cancer. 5(suppl 2):S53-S59; 5(suppl 3):S85-S91. Androgen receptor Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1):S3-S10. Petrylak DP. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Androgen replacement Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1):S29-S33. McCullough A. Case scenarios in androgen deficiency. 5(suppl 1):S41-S48. Rajfer J. Androgen replacement and quality of life [Literature Review]. 5(3):206-207. Androgen suppression therapy D’Amico AV. Therapeutic strategies for locally and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. 5(suppl 6):S40-S46. Andropause Heaton JPW. Hormone treatments and preventive strategies in the aging male: whom and when to treat? 5(suppl 1):S16-S21. VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY 255 Subject Index continued Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Steidle CP. New advances in the treatment of hypogonadism in the aging male. 5(suppl 1):S34-S40. Anticholinergic agents Appell RA. Overactive bladder in special populations. 5(suppl 8):S37-S41. Antimuscarinic agents MacDiarmid S. Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Antisense oligonucleotides Syed S, Tolcher A. Innovative therapies for prostate cancer treatment. 5(suppl 3):S78-S84. Apormorphine Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 5(suppl 7):S9-S20. Artificial neural networks Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Assisted reproductive technology O’Leary MP. Weighing cost versus efficacy in assisted reproductive technology [Literature Review]. 5(4):247. Atrasentan Petrylak DP. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Bacille Calmette-Guérin Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Benign prostatic enlargement Slawin KM. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4):S42-S47; 5(suppl 5):S36-S41. Benign prostatic hyperplasia Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. 5(2):72-80. Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. 5(suppl 5):S42-S48. Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5): S28-S35. McVary KT. Clinical evaluation of benign prostatic hyperplasia. 5(suppl 4):S3-S11; 5(suppl 5):S3-S11. Nickel JC. Benign prostatic hyperplasia: case scenarios. 5(suppl 4):S48-S49. Nickel JC. Benign prostatic hyperplasia: does prostate size matter? 5(suppl 4):S12-S17. 256 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY Roehrborn CG. 5--Reductase inhibitors prevent the progression of benign prostatic hyperplasia. 5(suppl 4):S18-S27; 5(suppl 5):S12-S21. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Slawin KM. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4):S42-S47; 5(suppl 5):S36-S41. Vaughan ED. Long-term experience with 5-reductase inhibitors. 5(suppl 4):S28-S33; 5(suppl 5):S22-S27. Benign prostatic hypertrophy Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Bicalutamide Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Biochemical relapse Taplin M-E. Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Bisphosphonates Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Khan MA, Partin AW. Bisphosphonates in metastatic prostate cancer [Literature Review]. 5(3):204-206. Bladder cancer Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Gretzer MB, Partin AW, Chan DW, Veltri RW. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). 5(2):81-89. Palapattu GS, Kim HL, Belldegrun AS. Advances in the treatment of genitourinary cancer [Meeting Review]. 5(4):232-234. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Bladder health questionnaire Chermansky CJ, Chancellor MB. Increasing awareness and improving the care of urinary incontinence [Meeting Review]. 5(1):22-25. Bladder outlet obstruction Nickel JC. Benign prostatic hyperplasia: does prostate size matter? 5(suppl 4):S12-S17. Slawin KM. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4):S42-S47; 5(suppl 5):S36-S41. Bone mineral density Heaton JPW. Hormone treatments and pre- ventive strategies in the aging male: whom and when to treat? 5(suppl 1):S16-S21. Calcitriol Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Henner WD, Beer TM. A new formulation of calcitriol (DN-101) for high-dose pulse administration in prostate cancer therapy. 5(suppl 3):S38-S44. Calcium oxalate stones Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Cancer staging Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. CaP CURE Soule HR. CaP CURE initiatives and projects. 5(suppl 2):S60-S65; 5(suppl 3):S92-S97. Capsaicin Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. 5(suppl 8):S3-S10. Carbonic anhydrase inhibitors Matlaga BR, Shah OD, Assimos DG. Druginduced urinary calculi. 5(4):227-231. Chemoprevention Crawford ED. Complementary medicine, chemoprevention, and staging of prostate cancer. 5(suppl 6):S23-S32. Khan MA, Partin AW. Chemoprevention and prostate cancer [Literature Review]. 5(1):61-63. Chemotherapy Crawford ED. The role of the urologist in treating patients with hormone-refractory prostate cancer. 5(suppl 2):S48-S52. Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42S47; 5(suppl 3):S59-S64. Kent EC, Hussain MHA. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28-S37. Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. 5(suppl 2):S14-S21; 5(suppl 3):S14-S21. Sandler HM, Pienta KJ. Rationale for the radiation therapy oncology group study RTOG P-0014. 5(suppl 2):S28-S34; 5(suppl 3): S45-S51. Chronic pelvic pain syndrome Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Chronic prostatitis Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Subject Index Clinical evaluation McVary KT. Clinical evaluation of benign prostatic hyperplasia. 5(suppl 4):S3-S11; 5(suppl 5):S3-S11. Color Doppler imaging Brawer MK. Early diagnosis and staging of prostate cancer. 5(suppl 6):S17-S22. Combined chemohormonal therapy Taplin M-E. Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Complementary medicine Crawford ED. Complementary medicine, chemoprevention, and staging of prostate cancer. 5(suppl 6):S23-S32. Coronary heart disease Stein RA. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 5(suppl 7):S21-S27. Cost-of-illness Chermansky CJ, Chancellor MB. Increasing awareness and improving the care of urinary incontinence [Meeting Review]. 5(1):22-25. Cross-trigonal repair Shapiro E, Snow B, Zaontz M. Management of vesicoureteral reflux. 5(2):121-125. Cytoscopy Lenz DL, Harpster LE. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. 5(1):49-53. Deflux Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Dendritic cells Amato RJ. Vaccine therapy for renal cell carcinoma. 5(2):65-71. Depression Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Detrusorrhaphy Shapiro E, Snow B, Zaontz M. Management of vesicoureteral reflux. 5(2):121-125. Diagnosis Brawer MK. Assays for complexed prostatespecific antigen and other advances in the diagnosis of prostate cancer. 5(suppl 6):S10S16. Brawer MK. Early diagnosis and staging of prostate cancer. 5(suppl 6):S17-S22. Taneja SS. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. 5(3):149-155. Dihydrotestosterone Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1): S29-S33. Vaughan ED. Long-term experience with 5-reductase inhibitors. 5(suppl 4):S28-S33; 5(suppl 5):S22-S27. Disease progression Roehrborn CG. 5--Reductase inhibitors prevent the progression of benign prostatic hyperplasia. 5(suppl 4):S18-S27; 5(suppl 5): S12-S21. Distal ureteral calculi Shah OD, Matlaga BR, Assimos DG. Selecting treatment for distal ureteral calculi: shock wave lithotripsy versus ureteroscopy. 5(1):40-44. Docetaxel Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Dreicer R, Carducci M. E-1899: an eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. 5(suppl 2):S35-S41; 5(suppl 3):S52-S58. Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42S47; 5(suppl 3):S59-S64. Henner WD, Beer TM. A new formulation of calcitriol (DN-101) for high-dose pulse administration in prostate cancer therapy. 5(suppl 3):S38-S44. Klein EA, Dreicer R. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. 5(suppl 2):S22-S27; 5(suppl 3):S22-S27. Kumar P. A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. 5(suppl 3):S71-S77. Dutasteride Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Early detection Wilt TJ. Prostate cancer: epidemiology and screening. 5(suppl 6):S3-S9. Endothelial system McCullough AR. The penis as a barometer of endothelial health. 5(suppl 7):S3-S8. Endothelin Rajfer J. Recent findings in impotence research [Meeting Review]. 5(2):118-120. Endothelium Stein RA. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 5(suppl 7):S21-S27. Endourology Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Ephedrine Matlaga BR, Shah OD, Assimos DG. Druginduced urinary calculi. 5(4):227-231. Epidermal growth factors Brawer MK. Assays for complexed prostatespecific antigen and other advances in the diagnosis of prostate cancer. 5(suppl 6):S10S16. Epididymectomy Nickel JC. Chronic epididymitis: a practical approach to understanding and managing a difficult urologic enigma. 5(4):209-215. Leonard GD, Dahut WL, Gulley JL, et al. Docetaxel and thalidomide as a treatment option for androgen-independent, nonmetastatic prostate cancer. 5(suppl 3):S65-S70. Epididymitis Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. 5(suppl 2):S14-S21; 5(suppl 3):S14-S21. Epothilones Syed S, Tolcher A. Innovative therapies for prostate cancer treatment. 5(suppl 3):S78-S84. Dosing Tenover JL. The androgen-deficient aging male: current treatment options. 5(suppl 1): S22-S28. Doxazosin Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5): S28-S35. Duloxetine Cannon TW, Chancellor MB. Pharmacotherapy for stress urinary incontinence. 5(3):135-141. Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Nickel JC. Chronic epididymitis: a practical approach to understanding and managing a difficult urologic enigma. 5(4):209-215. Petrylak DP. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Erectile dysfunction Barada JH. Optimizing outcomes of oral therapy for patients with erectile dysfunction. 5(suppl 7):S28-S34. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 5(suppl 7):S9-S20. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. 5(2):72-80. Heaton JPW. Hormone treatments and preventive strategies in the aging male: whom and when to treat? 5(suppl 1):S16-S21. Jalkut M, Gonzalez-Cadavid N, Rajfer J. Peyronie’s disease: a review. 5(3):142-148. Lepor H. Surgical, pharmacological, and VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY 257 Subject Index continued technological advances in adult and pediatric urology—state of the art [Meeting Review]. 5(1):29-39. Gene regulation McCullough A. Case scenarios in androgen deficiency. 5(suppl 1):S41-S48. Genitourinary oncology McCullough AR. The penis as a barometer of endothelial health. 5(suppl 7):S3-S8. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. O’Leary MP. A new quality-of-life scoring instrument for patients with erectile dysfunction [Literature Review]. 5(4):247. Rajfer J. Recent findings in impotence research [Meeting Review]. 5(2):118-120. Sadovsky R. Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. 5(suppl 7): S35-S48. Steidle CP. New advances in the treatment of hypogonadism in the aging male. 5(suppl 1):S34-S40. Stein RA. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 5(suppl 7):S21-S27. Estramustine Dreicer R, Carducci M. E-1899: an eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. 5(suppl 2):S35-S41; 5(suppl 3):S52-S58. Expectant management Khan MA, Partin AW. Expectant management of prostate cancer [Literature Review]. 5(4):247-250. Wilt TJ. Prostate cancer: epidemiology and screening. 5(suppl 6):S3-S9. External beam radiation therapy D’Amico AV. Therapeutic strategies for locally and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. 5(suppl 6):S40-S46. Exisuland Petrylak DP. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Finasteride Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5): S28-S35. Roehrborn CG. 5--Reductase inhibitors prevent the progression of benign prostatic hyperplasia. 5(suppl 4):S18-S27; 5(suppl 5): S12-S21. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Vaughan ED. Long-term experience with 5-reductase inhibitors. 5(suppl 4):S28-S33; 5(suppl 5):S22-S27. 258 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Palapattu GS, Kim HL, Belldegrun AS. Advances in the treatment of genitourinary cancer [Meeting Review]. 5(4):232-234. Geriatrics Appell RA. Overactive bladder in special populations. 5(suppl 8):S37-S41. Germ-cell tumor Kim HL, Han K-R, Belldegrun AS. Late relapse of germ-cell tumor [Literature Review]. 5(3):207-208. Gleason score Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Graft-based techniques Jalkut M, Gonzalez-Cadavid N, Rajfer J. Peyronie’s disease: a review. 5(3):142-148. Guanylate cyclase activators Rajfer J. Recent findings in impotence research [Meeting Review]. 5(2):118-120. Heat shock proteins Amato RJ. Vaccine therapy for renal cell carcinoma. 5(2):65-71. Hemostasis Lee BR. Laparoscopic total and partial nephrectomy—the new standard? 5(1):9-14. Hereditary nonpolyposis colon cancer Lenz DL, Harpster LE. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. 5(1):49-53. High-dose pulse administration Henner WD, Beer TM. A new formulation of calcitriol (DN-101) for high-dose pulse administration in prostate cancer therapy. 5(suppl 3):S38-S44. High-grade prostatic intraepithelial neoplasia study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42S47; 5(suppl 3):S59-S64. Gretzer MB, Partin AW. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. 5(suppl 2):S14-S21; 5(suppl 3):S14-S21. Sandler HM, Pienta KJ. Rationale for the radiation therapy oncology group study RTOG P-0014. 5(suppl 2):S28-S34; 5(suppl 3):S45-S51. Syed S, Tolcher A. Innovative therapies for prostate cancer treatment. 5(suppl 3):S78S84. Taneja SS. A multidisciplinary approach to the management of hormone-refractory prostate cancer. 5(suppl 2):S53-S59; 5(suppl 3): S85-S91. Hormone replacement therapy Assimos DG. Hormone replacement therapy and postmenopausal stone-formers [Literature Review]. 5(2):130. Kwon DD, Chancellor MB. The estrogen controversy [Literature Review]. 5(2):131-132. Meacham RB. Androgen replacement therapy: treatment advances and clinical implications [Literature Review]. 5(4):245-247. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Hydronephrosis Shapiro E, Snow B, Zaontz M. Management of vesicoureteral reflux. 5(2):121-125. Hypercalcemia Henner WD, Beer TM. A new formulation of calcitriol (DN-101) for high-dose pulse administration in prostate cancer therapy. 5(suppl 3):S38-S44. Hypertension Gretzer MB, Partin AW. 54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy. 5(1):45-48. Shapiro E, Goldfarb DA, Ritchey ML. The congenital and acquired solitary kidney. 5(1):2-8. Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology—state of the art [Meeting Review]. 5(1):29-39. Hypogonadism Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1):S29-S33. Histopathology Tewari A. Management of clinically localized prostate cancer: pathologic processing to robotic prostatectomy. 5(suppl 6):S33-S39. Hormonal therapy Kent EC, Hussain MHA. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28-S37. Rajfer J. Androgen replacement and quality of life [Literature Review]. 5(3):206-207. Hormone-refractory prostate cancer Crawford ED. The role of the urologist in treating patients with hormone-refractory prostate cancer. 5(suppl 2):S48-S52. Eisenberger MA. A multi-institutional pilot Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1): S3-S10. McCullough A. Case scenarios in androgen deficiency. 5(suppl 1):S41-S48. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216226. Steidle CP. New advances in the treatment of hypogonadism in the aging male. 5(suppl 1):S34-S40. Ileocystoplasty Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Subject Index Impotence Sadovsky R. Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. 5(suppl 7): S35-S48. Incontinence Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Chermansky CJ, Chancellor MB. Increasing awareness and improving the care of urinary incontinence [Meeting Review]. 5(1):22-25. Kim J, Chancellor MB. New approaches to the treatment of overactive bladder: the purine pathways and an update on the tension-free vaginal tape sling [Literature Review]. 5(1):59-60. Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology—state of the art [Meeting Review]. 5(1):29-39. MacDiarmid S. Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Indinavir Matlaga BR, Shah OD, Assimos DG. Druginduced urinary calculi. 5(4):227-231. Infertility Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology—state of the art [Meeting Review]. 5(1):29-39. O’Leary MP. Weighing cost versus efficacy in assisted reproductive technology [Literature Review]. 5(4):251. Intermittent hormonal therapy Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. International Prostate Symptom Score Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Interstitial cystitis Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Ketoconazole Dreicer R, Carducci M. E-1899: an eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. 5(suppl 2):S35-S41; 5(suppl 3): S52-S58. Kidney cancer Palapattu GS, Kim HL, Belldegrun AS. Advances in the treatment of genitourinary cancer [Meeting Review]. 5(4):232-234. Palapttu GS, Kim HL, Belldegrun AS. Lymph node dissection in patients with kidney cancer: when is it indicated? 5(3):196-199. Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Kidney donor Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1): 26-28. Shapiro E, Goldfarb DA, Ritchey ML. The congenital and acquired solitary kidney. 5(1):2-8. Kidney injury Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Kidney stones Assimos DG. Hormone replacement therapy and postmenopausal stone-formers [Literature Review]. 5(2):130. Assimos DG. Low-calcium, low-sodium, and low-animal protein diet for stone prevention [Literature Review]. 5(1):60-61. Lymphadenectomy Laparoscopic radical nephrectomy Male infertility Lee BR. Laparoscopic total and partial nephrectomy—the new standard? 5(1):9-14. Laparoscopic surgery Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Locally advanced prostate cancer Klein EA, Dreicer R. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. 5(suppl 2):S22-S27; 5(suppl 3):S22-S27. Lower urinary tract symptoms Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. 5(2):72-80. Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5): S28-S35. McVary KT. Clinical evaluation of benign prostatic hyperplasia. 5(suppl 4):S3-S11; 5(suppl 5):S3-S11. Roehrborn CG. 5--Reductase inhibitors prevent the progression of benign prostatic hyperplasia. 5(suppl 4):S18-S27; 5(suppl 5): S12-S21. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Slawin KM. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4):S42-S47; 5(suppl 5):S36-S41. Luteinizing hormone Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1): S3-S10. Brawer MK. Early diagnosis and staging of prostate cancer. 5(suppl 6):S17-S22. Freedland SJ, deKernion JB. Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma. 5(3):191-195. Palapattu GS, Kim HL, Belldegrun AS. Lymph node dissection in patients with kidney cancer: when is it indicated? 5(3):196-199. Lymph node dissection Freedland SJ, deKernion JB. Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma. 5(3):191-195. Palapattu GS, Kim HL, Belldegrun AS. Lymph node dissection in patients with kidney cancer: when is it indicated? 5(3):196-199. Magnetic resonance imaging Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Niederberger CS, Meacham RB. Male infertility. 5(3):200. Male osteoporosis Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Markers Gretzer MB, Partin AW, Chan DW, Veltri RW. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). 5(2):81-89. Men’s health Sadovsky R. Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. 5(suppl 7):S35-S48. Microtubule Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. 5(suppl 2):S14-S21; 5(suppl 3):S14-S21. Miralax Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Mixed incontinence MacDiarmid S. Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Monotherapy Kim HL, Han K-R, Belldegrun AS. Late relapse of germ-cell tumor [Literature Review]. 5(3):207-208. MTOPS Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Multidisciplinary treatment Taneja SS. A multidisciplinary approach to the management of hormone-refractory prostate cancer. 5(suppl 2):S53-S59; 5(suppl 3): S85-S91. VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY 259 Subject Index continued Muscarinic receptors Dmochowski RR. Treatment of the overactive bladder: where we stand in 2003. 5(suppl 8):S11-S17. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. 5(suppl 8):S3-S10. Neoadjuvant chemotherapy Kent EC, Hussain MHA. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28-S37. Klein EA, Dreicer R. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. 5(suppl 2):S22-S27; 5(suppl 3):S22-S27. Nephrectomy Palapattu GS, Kim HL, Belldegrun AS. Lymph node dissection in patients with kidney cancer: when is it indicated? 5(3):196-199. Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Shapiro E, Goldfarb DA, Ritchey ML. The congenital and acquired solitary kidney. 5(1):2-8. Nephrolithiasis Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Matlaga BR, Shah OD, Assimos DG. Druginduced urinary calculi. 5(4):227-231. Neural pathways Rajfer J. Recent findings in impotence research [Meeting Review]. 5(2):118-120. Nitric oxide synthase McCullough AR. The penis as a barometer of endothelial health. 5(suppl 7):S3-S8. Nomograms Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42S47; 5(suppl 3):S59-S64. Overactive bladder Appell RA. Overactive bladder in special populations. 5(suppl 8):S37-S41. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Chermansky CJ, Chancellor MB. Increasing awareness and improving the care of urinary incontinence [Meeting Review]. 5(1):22-25. Dmochowski RR. Treatment of the overactive bladder: where we stand in 2003. 5(suppl 8):S11-S17. Kim J, Chancellor MB. New approaches to the treatment of overactive bladder: the purine pathways and an update on the tension-free vaginal tape sling [Literature Review]. 5(1):59-60. Nitti VW. Transdermal therapy for overactive bladder: present and future. 5(suppl 8): S31-S36. Staskin DR. Transdermal systems for overactive bladder: principles and practice. 5(suppl 8):S26-S30. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. 5(suppl 8):S3-S10. Oxybutynin Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Dmochowski RR. Treatment of the overactive bladder: where we stand in 2003. 5(suppl 8):S11-S17. MacDiarmid S. Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Nitti VW. Transdermal therapy for overactive bladder: present and future. 5(suppl 8): S31-S36. Gretzer MB, Partin AW. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. Staskin DR. Transdermal systems for overactive bladder: principles and practice. 5(suppl 8):S26-S30. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. 5(suppl 8):S3-S10. Obstructive sleep apnea Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Osteoporosis Steidle CP. New advances in the treatment of hypogonadism in the aging male. 5(suppl 1): S34-S40. Outcomes Barada JH. Optimizing outcomes of oral therapy for patients with erectile dysfunction. 5(suppl 7):S28-S34. 260 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY Palliative therapy Leonard GD, Dahut WL, Gulley JL, et al. Docetaxel and thalidomide as a treatment option for androgen-independent, nonmetastatic prostate cancer. 5(suppl 3):S65-S70. Partial androgen deficiency McCullough A. Case scenarios in androgen deficiency. 5(suppl 1):S41-S48. Partial nephrectomy Lee BR. Laparoscopic total and partial nephrectomy—the new standard? 5(1):9-14. Pathology Brawer MK. Assays for complexed prostate- specific antigen and other advances in the diagnosis of prostate cancer. 5(suppl 6):S10S16. Pediatric urology Appell RA. Overactive bladder in special populations. 5(suppl 8):S37-S41. Shapiro E. 3-month-old boy with a febrile urinary tract infection. 5(4):241-244. Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Pelvic organ prolapse Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Permixon Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Peyronie’s disease Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Jalkut M, Gonzalez-Cadavid N, Rajfer J. Peyronie’s disease: a review. 5(3):142-148. Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology- state of the art [Meeting Review]. 5(1):29-39. Phosphodiesterase-5 inhibitors Barada JH. Optimizing outcomes of oral therapy for patients with erectile dysfunction. 5(suppl 7):S28-S34. McCullough AR. The penis as a barometer of endothelial health. 5(suppl 7):S3-S8. Rajfer J. Recent findings in impotence research [Meeting Review]. 5(2):118-120. Stein RA. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 5(suppl 7):S21-S27. PLESS Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Plication techniques Jalkut M, Gonzalez-Cadavid N, Rajfer J. Peyronie’s disease: a review. 5(3):142-148. Prenatal hydronephrosis Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology- state of the art [Meeting Review]. 5(1):29-39. Prostate biopsy Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Taneja SS. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. 5(3):149-155. Subject Index Prostate cancer Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1): S29-S33. Brawer MK. Assays for complexed prostatespecific antigen and other advances in the diagnosis of prostate cancer. 5(suppl 6):S10S16. Brawer MK. Early diagnosis and staging of prostate cancer. 5(suppl 6):S17-S22. Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Crawford ED. Complementary medicine, chemoprevention, and staging of prostate cancer. 5(suppl 6):S23-S32. D’Amico AV. Therapeutic strategies for locally and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. 5(suppl 6):S40-S46. Dreicer R, Carducci M. E-1899: an eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. 5(suppl 2):S35-S41; 5(suppl 3): S52-S58. Gretzer MB, Partin AW, Chan DW, Veltri RW. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). 5(2):81-89. Kent EC, Hussain MHA. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28-S37. Khan MA, Partin AW. Bisphosphonates in metastatic prostate cancer [Literature Review]. 5(3):204-206. Khan MA, Partin AW. Chemoprevention and prostate cancer [Literature Review]. 5(1):61-63. Khan MA, Partin AW. Expectant management of prostate cancer [Literature Review]. 5(4):247-250. Kumar P. A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. 5(suppl 3):S71-S77. McCullough A. Case scenarios in androgen deficiency. 5(suppl 1):S41-S48. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Palapattu GS, Kim HL, Belldegrun AS. Advances in the treatment of genitourinary cancer [Meeting Review]. 5(4):232-234. Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Petrylak DP. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Sandler HM, Pienta KJ. Rationale for the radiation therapy oncology group study RTOG P-0014. 5(suppl 2):S28-S34; 5(suppl 3): S45-S51. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Shariat SF, Slawin KM. Peripheral blood RTPCR assays for detection and prognosis of prostate cancer [Literature Review]. 5(1):54-58. Soule HR. CaP CURE initiatives and projects. 5(suppl 2):S60-S65; 5(suppl 3):S92-S97. Taneja SS. A multidisciplinary approach to the management of hormone-refractory prostate cancer. 5(suppl 2):S53-S59; 5(suppl 3): S85-S91. Taneja SS. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. 5(3):149-155. Taplin M-E. Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Tewari A. Management of clinically localized prostate cancer: pathologic processing to robotic prostatectomy. 5(suppl 6):S33-S39. Wilt TJ. Prostate cancer: epidemiology and screening. 5(suppl 6):S3-S9. Prostate cancer progression Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Prostate cancer staging Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Prostate rebiopsy Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Prostate-specific antigen Anagnostou T, Remzi M, Djavan B. Artificial neural networks for decision-making in urologic oncology. 5(1):15-21. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1): S29-S33. Brawer MK. Assays for complexed prostatespecific antigen and other advances in the diagnosis of prostate cancer. 5(suppl 6):S10S16. D’Amico AV. Therapeutic strategies for locally and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. 5(suppl 6):S40-S46. Gretzer MB, Partin AW. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. Nickel JC. Benign prostatic hyperplasia: does prostate size matter? 5(suppl 4):S12-S17. Petrylak DP. Docetaxel for the treatment of hormone-refractory prostate cancer. 5(suppl 2):S14-S21; 5(suppl 3):S14-S21. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Soule HR. CaP CURE initiatives and projects. 5(suppl 2):S60-S65; 5(suppl 3):S92-S97. Taneja SS. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. 5(3):149-155. Taplin M-E. Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Prostate tumor markers Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Prostate volume Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5): S28-S35. Nickel JC. Benign prostatic hyperplasia: does prostate size matter? 5(suppl 4):S12-S17. Prostatectomy Taplin M-E. Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Prostatic ethanol injection Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Prosthesis Jalkut M, Gonzalez-Cadavid N, Rajfer J. Peyronie’s disease: a review. 5(3):142-148. Proteomics Gretzer MB, Partin AW, Chan DW, Veltri RW. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). 5(2):81-89. PS-341 Petrylak DP. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Pyelonephritis Shapiro E, Snow B, Zaontz M. Management of vesicoureteral reflux. 5(2):121-125. Quality of life Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. 5(2):72-80. Chermansky CJ, Chancellor MB. Increasing awareness and improving the care of urinary incontinence [Meeting Review]. 5(1):22-25. O’Leary MP. A new quality-of-life scoring instrument for patients with erectile dysfunction [Literature Review]. 5(4):247. O’Leary MP. Development of an index to evaluate symptoms in men with androgen deficiency. 5(suppl 1):S11-S15. Radiation therapy Taplin M-E. Biochemical (prostate-specific VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY 261 Subject Index continued antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Radical nephrectomy Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Radical prostatectomy Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Eisenberger MA. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42S47; 5(suppl 3):S59-S64. Kent EC, Hussain MHA. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28-S37. Klein EA, Dreicer R. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. 5(suppl 2):S22-S27; 5(suppl 3):S22-S27. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Tewari A. Management of clinically localized prostate cancer: pathologic processing to robotic prostatectomy. 5(suppl 6):S33-S39. Radiofrequency ablation Lee BR. Laparoscopic total and partial nephrectomy—the new standard? 5(1):9-14. Radioimmunoscintigraphy Gretzer MB, Partin AW. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. Radiosensitization Kumar P. A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. 5(suppl 3):S71-S77. Radiotherapy Advances in the medical treatment of prostate cancer, bladder cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Renal cell carcinoma Amato RJ. Vaccine therapy for renal cell carcinoma. 5(2):65-71. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Freedland SJ, deKernion JB. Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma. 5(3):191-195. Renal neoplasms Lee BR. Laparoscopic total and partial nephrectomy—the new standard? 5(1):9-14. Renal transplantation Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Resiniferatoxin Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Reverse transcriptase polymerase chain reaction Shariat SF, Slawin KM. Peripheral blood RTPCR assays for detection and prognosis of prostate cancer [Literature Review]. 5(1):54-58. Robotically assisted laparoscopic surgery Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Robotics Tewari A. Management of clinically localized prostate cancer: pathologic processing to robotic prostatectomy. 5(suppl 6):S33-S39. Sarcopenia Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Scrotal pain Nickel JC. Chronic epididymitis: a practical approach to understanding and managing a difficult urologic enigma. 5(4):209-215. Gretzer MB, Partin AW. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. SELDI-TOF Kent EC, Hussain MHA. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28-S37. Serotonin Reimbursement Crawford ED. The role of the urologist in treating patients with hormone-refractory prostate cancer. 5(suppl 2):S48-S52. Renal cancer Gretzer MB, Partin AW, Chan DW, Veltri RW. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). 5(2):81-89. Seitz C, Remzi M, Djavan B, Roehrborn CG. 262 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Cannon TW, Chancellor MB. Pharmacotherapy for stress urinary incontinence. 5(3):135-141. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. 5(suppl 8):S3-S10. Sex hormone binding-globulin Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1): S3-S10. Sexual dysfunction Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. 5(2):72-80. Sexual history Sadovsky R. Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. 5(suppl 7): S35-S48. Sexual therapy Barada JH. Optimizing outcomes of oral therapy for patients with erectile dysfunction. 5(suppl 7):S28-S34. Sadovsky R. Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. 5(suppl 7): S35-S48. Shared decision making Wilt TJ. Prostate cancer: epidemiology and screening. 5(suppl 6):S3-S9. Shock wave lithotripsy Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Shah OD, Matlaga BR, Assimos DG. Selecting treatment for distal ureteral calculi: shock wave lithotripsy versus ureteroscopy. 5(1):40-44. Sildenafil Barada JH. Optimizing outcomes of oral therapy for patients with erectile dysfunction. 5(suppl 7):S28-S34. Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 5(suppl 7):S9-S20. Stein RA. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 5(suppl 7):S21-S27. Skin reactions Nitti VW. Transdermal therapy for overactive bladder: present and future. 5(suppl 8): S31-S36. Society of Urologic Oncology Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Staging Brawer MK. Early diagnosis and staging of prostate cancer. 5(suppl 6):S17-S22. Crawford ED. Complementary medicine, chemoprevention, and staging of prostate cancer. 5(suppl 6):S23-S32. Stents Shah OD, Matlaga BR, Assimos DG. Selecting treatment for distal ureteral calculi: shock wave lithotripsy versus ureteroscopy. 5(1):40-44. Stress urinary incontinence Cannon TW, Chancellor MB. Pharmacotherapy for stress urinary incontinence. 5(3):135-141. Subject Index Subureteric injection Shapiro E, Snow B, Zaontz M. Management of vesicoureteral reflux. 5(2):121-125. Sulfa medications Matlaga BR, Shah OD, Assimos DG. Druginduced urinary calculi. 5(4):227-231. Surgical therapy MacDiarmid S. Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Symptom index O’Leary MP. Development of an index to evaluate symptoms in men with androgen deficiency. 5(suppl 1):S11-S15. Tadalafil Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 5(suppl 7):S9-S20. Rajfer J. Recent findings in impotence research [Meeting Review]. 5(2):118-120. Tamsulosin Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Targeted therapies Carducci MA. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. Tension-free vaginal tape Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Terazosin Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5): S28-S35. Testicular cancer Palapattu GS, Kim HL, Belldegrun AS. Advances in the treatment of genitourinary cancer [Meeting Review]. 5(4):232-234. Testicular pain Nickel JC. Chronic epididymitis: a practical approach to understanding and managing a difficult urologic enigma. 5(4):209-215. Testis injury Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Testosterone Heaton JPW. Hormone treatments and preventive strategies in the aging male: whom and when to treat? 5(suppl 1):S16-S21. Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1): S3-S10. Myers JB, Meacham RB. Androgen replacement therapy in the aging male. 5(4):216-226. Testosterone preparations Tenover JL. The androgen-deficient aging male: current treatment options. 5(suppl 1): S22-S28. Testosterone replacement therapy Steidle CP. New advances in the treatment of hypogonadism in the aging male. 5(suppl 1): S34-S40. Thalidomide Leonard GD, Dahut WL, Gulley JL, et al. Docetaxel and thalidomide as a treatment option for androgen-independent, nonmetastatic prostate cancer. 5(suppl 3):S65-S70. Thermal ablation Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Three-dimensional conformal radiation therapy Kumar P. A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. 5(suppl 3):S71-S77. Tolterodine tartrate Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Dmochowski RR. Treatment of the overactive bladder: where we stand in 2003. 5(suppl 8):S11-S17. MacDiarmid S. Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Total colpocleisis Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Training Crawford ED. The role of the urologist in treating patients with hormone-refractory prostate cancer. 5(suppl 2):S48-S52. Transdermal drug delivery Nitti VW. Transdermal therapy for overactive bladder: present and future. 5(suppl 8): S31-S36. Staskin DR. Transdermal systems for overactive bladder: principles and practice. 5(suppl 8):S26-S30. Transitional cell carcinoma Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Transrectal ultrasound-guided biopsy Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Taneja SS. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. 5(3):149-155. Unilateral renal agenesis Shapiro E, Goldfarb DA, Ritchey ML. The congenital and acquired solitary kidney. 5(1):2-8. Ureteropelvic junction obstruction Shah O, Matlaga BR, Assimos DG. 20-yearold male with recurrent right flank pain. 5(2):126-129. Ureteroscopy Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Shah OD, Matlaga BR, Assimos DG. Selecting treatment for distal ureteral calculi: shock wave lithotripsy versus ureteroscopy. 5(1):40-44. Urethra Cannon TW, Chancellor MB. Pharmacotherapy for stress urinary incontinence. 5(3):135-141. Urinalysis Lenz DL, Harpster LE. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. 5(1):49-53. Urinary calculi Matlaga BR, Shah OD, Assimos DG. Druginduced urinary calculi. 5(4):227-231. Urinary flow rate McVary KT. Clinical evaluation of benign prostatic hyperplasia. 5(suppl 4):S3-S11; 5(suppl 5):S3-S11. Urinary tract infection Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Nickel JC. Management of urinary tract infections in children: simplifying the controversies? [Literature Review]. 5(2):132-134. Shapiro E. 3-month-old boy with a febrile urinary tract infection. 5(4):241-244. Urine cytology Lenz DL, Harpster LE. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. 5(1):49-53. Urothelial carcinoma Lenz DL, Harpster LE. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. 5(1):49-53. Uryx Cannon TW, Howden N, Xavier M, Chancellor MB. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Vaccines Amato RJ. Vaccine therapy for renal cell carcinoma. 5(2):65-71. Vardenafil Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 5(suppl 7):S9-S20. VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY 263 Subject Index continued Varicocele Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology—state of the art [Meeting Review]. 5(1):29-39. Vasculopathy McCullough AR. The penis as a barometer of endothelial health. 5(suppl 7):S3-S8. Vesicoureteral reflux Lepor H. Surgical, pharmacological, and technological advances in adult and pedi- 264 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY atric urology—state of the art [Meeting Review]. 5(1):29-39. Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Shapiro E, Snow B, Zaontz M. Management of vesicoureteral reflux. 5(2):121-125. Virtual cytoscopy Seitz C, Remzi M, Djavan B, Roehrborn CG. Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Virtual ureteroscopy Assimos DG. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182-185. Voiding dysfunction Lepor H. Surgical, pharmacological, and technological advances in adult and pediatric urology- state of the art [Meeting Review]. 5(1):29-39. Shapiro E. Updates in pediatric urology [Meeting Review]. 5(3):186-190.